Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -119K | -186K | -183K | -118K | -119K |
| Operating Income | -8M | -7M | -9M | -18M | -24M |
| EBITDA | -7M | -6M | -8M | -17M | -13M |
| Net Income | -7M | -6M | -8M | -18M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$7.54
-5.16% today
1Y Change
+291.79%
Window
Jun 26, 2025 → Jun 23, 2026
Coverage: 248 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Edesa Biotech, Inc. (EDSA) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $7.54 and up 291.8% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +34.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +34.2%, free cash flow -49.7% with operating margin 0.0% and ROIC -59.9%. Stock Foundry combines EDSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EDSA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EDSA Max Drawdown
-72.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for EDSA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$13.3M
+24.0% YoY
Free Cash Flow
-$13.7M
-11.3% YoY
Revenue Growth
+0.0%
EPS Growth
+34.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -119K | -186K | -183K | -118K | -119K |
| Operating Income | -8M | -7M | -9M | -18M | -24M |
| EBITDA | -7M | -6M | -8M | -17M | -13M |
| Net Income | -7M | -6M | -8M | -18M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 1M | 5M | 7M | 8M |
| Total Assets | 14M | 4M | 9M | 12M | 15M |
| Total Liabilities | 1M | 2M | 2M | 2M | 2M |
| Shareholder Equity | 12M | 2M | 7M | 9M | 13M |
| Total Debt | 0 | 20K | 94K | 19K | 99K |
| Net Debt | -11M | -1M | -5M | -7M | -8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14M
-11.3% YoY
Capital Expenditures
6K
-8.7% YoY
Free Cash Flow
14M
-11.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.